cabergoline has been researched along with Hyperprolactinemia in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (3.09) | 18.7374 |
| 1990's | 28 (14.43) | 18.2507 |
| 2000's | 64 (32.99) | 29.6817 |
| 2010's | 71 (36.60) | 24.3611 |
| 2020's | 25 (12.89) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, MF; Akter, R; Al-Harrasi, A; Berrada, M; Bhatia, S; Damiri, F; Ferdous Mitu, J; Kabir, MT; Rahman, MH; Rahman, MS; Saleem, A | 1 |
| Hamidianjahromi, A; Tritos, NA | 1 |
| Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R | 1 |
| Leshchenko, OY | 1 |
| Berberoğlu, M; Bilici, E; Ceran, A; Kontbay, T; Özsu, E; Şıklar, Z; Uyanık, R | 1 |
| Bruehlman, RD; McKittrick, C; Winters, S | 1 |
| Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y | 1 |
| Cescato, VAS; Cunha-Neto, MBC; Glezer, A; Musolino, NRC; Pinheiro, FMM; Silva, GO; Stumpf, MAM | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Basiak, M; Krysiak, R; Machnik, G; Okopień, B; Szkróbka, W | 1 |
| Fathi, E; Panahi, Y; Shafiian, MA | 1 |
| Chang, TM; Chen, HA; Chien, YH; Hsu, RH; Hwu, WL; Lee, NC | 1 |
| Abucham, J; Boguszewski, CL; Bronstein, MD; Bueno, CB; Castro, M; Czepielewski, MA; Elias, PCL; Fontana, MLC; Francisco, RPV; Gadelha, MR; Garmes, HM; Glezer, A; Lyra, R; Marques, C; Martins, MRA; Musolino, NRC; Nazato, D; Nunes-Nogueira, VS; Portes, ES; Quidute, ARP; Ribeiro-Oliveira, A; Sant' Anna, BG; Vilar, L | 1 |
| Budayr, A; Go, AS; Lo, JC; Tabada, GH; Tan, TC; Yang, J; Zaroff, JG | 1 |
| Dehayem, M; Doh, E; Etoga, MCE; Foumane, P; Mbango-Ekouta, N; Mbanya, JC; Mekobe, FM; Ngoune, P; Sobngwi, E | 1 |
| Ahn, SS; Kim, D; Kim, EH; Kim, K; Ku, CR; Lee, EJ; Moon, JH; Park, YW | 1 |
| Bestwick, JP; Bhattacharyya, S; Boomla, K; Drake, WM; Lloyd, G; Steeds, RP; Stiles, CE | 1 |
| Beccuti, G; Cambria, V; Cicolin, A; Ghigo, E; Grottoli, S; Guaraldi, F; Lopiano, L; Montanaro, E; Natta, G; Prencipe, N; Zibetti, M | 1 |
| Akın, Ş; Candemir, B | 1 |
| Espinosa-Cárdenas, E; Mendoza-Zubieta, V; Mercado, M; Ramírez-Rentería, C; Sánchez-García, M; Sosa-Eroza, E | 1 |
| Abucham, J; Correa-Silva, SR; Portari, LHC | 1 |
| Duskin-Bitan, H; Gorshtein, A; Manisterski, Y; Masri, H; Rudman, Y; Shimon, I | 1 |
| Aberer, F; Obermayer-Pietsch, B; Pandis, M; Pieber, TR; Pilz, S; Posawetz, AS; Theiler-Schwetz, V; Trummer, C | 1 |
| Chen, TY; Cheng, WY; Chien, Y; Huang, YF; Lai, CM; Lee, CH; Shen, CC; Yang, MY; Yang, YP | 1 |
| Araujo, B; Belo, S; Carvalho, D | 1 |
| Caixàs, A; Caparrós, L; Giménez-Palop, O; Labad, J; Llorens, M; Montalvo, I; Palao, DJ; Pamias, M; Torralbas, J | 1 |
| Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
| Erdenebaatar, C; Honda, R; Katabuchi, H; Monsur, M; Ohba, T; Saito, F; Tashiro, H; Yamaguchi, M | 1 |
| Dalmolin, MD; Gadelha, MR; Kasuki, L; Wildemberg, LE | 1 |
| Huang, HY; Hui, GZ; Tang, H; Wu, ZB; Zhai, W | 1 |
| Abdullah, N; Aboelnaga, MM; Eladawy, EH; Elshafei, MM; Shaer, ME | 1 |
| Drake, WM; Steeds, RP; Stiles, CE | 1 |
| Caputo, C; Inder, WJ | 1 |
| Arosio, M; Ferrante, E; Giavoli, C; Indirli, R; Mantovani, G; Sala, E | 1 |
| Akirov, A; Barzilay-Yoseph, L; Eizenberg, Y; Fraenkel, M; Friedrich, I; Herzberg, D; Hirsch, D; Ishay, A; Livner, A; Manisterski, Y; Masri, H; Robenshtok, E; Shimon, I; Tsvetov, G; Yoel, U | 1 |
| Harris, K; Horn, D; MacGilivray, J; Murphy, KE; Yudin, MH | 1 |
| Barake, M; Biller, BM; Evins, AE; Klibanski, A; Miller, KK; Nachtigall, LB; Pachas, GN; Stoeckel, L; Tritos, NA | 1 |
| Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E | 1 |
| Bevan, JS; Drake, WM; Howlett, TA; Steeds, RP; Stiles, CE; Toogood, AA | 1 |
| Jensen, TS; Jørgensen, JO; Kallestrup, MM; Kasch, H; Nielsen, E; Østerby, T | 1 |
| Auriemma, RS; Colao, A; Galdiero, M; Gasperi, M; Giordano, C; Granieri, L; Mannarino, T; Negri, M; Perone, Y; Pivonello, C; Pivonello, R; Simeoli, C; Vitale, P | 1 |
| Andersen, M; Dal, J; Jørgensen, JO; Kistorp, C; Laurberg, P; Mægbæk, ML; Nørrelund, H; Steffensen, C | 1 |
| Barkan, A; Benbassat, C; Bronstein, MD; Shapiro, J; Shimon, I; Tsvetov, G | 1 |
| Macdonald, BK; Premaratne, VS; Saeger, I | 1 |
| Barambio-Ruíz, M; Córdoba-Soriano, JG; Hidalgo-Olivares, VM; Lamas-Oliveira, C; Salas-Nieto, J; Tercero-Martínez, A | 1 |
| Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R | 1 |
| Ezzat, S; Samson, SL | 1 |
| Bronstein, MD; Glezer, A | 1 |
| Krysiak, R; Okopien, B | 1 |
| Asicioglu, O; Aydin, K; Kucur, S; Temizkan, O; Temizkan, S | 1 |
| Ball, RL; Brown, JL; Morfeld, KA | 1 |
| Akbaba, G; Arduc, A; Aydin, Y; Berker, D; Gokay, F; Guler, S; Isik, S; Kucukler, FK; Ozuguz, U; Tutuncu, Y | 1 |
| Amital, H; Jeandel, PY; Shoenfeld, Y; Versini, M; Watad, A | 1 |
| Hu, J; Yang, H; Zhang, W; Zheng, X | 1 |
| Auriemma, RS; Cariati, F; Colao, A; Coppola, G; de Angelis, C; Ferreri, L; Galdiero, M; Granieri, L; Lo Calzo, F; Pivonello, C; Pivonello, R; Salzano, C; Vitale, P | 1 |
| Couldwell, WT; Eloy, JA; Liu, JK; Wong, A | 1 |
| Benbassat, C; Shimon, I; Tirosh, A | 1 |
| Couldwell, WT; Eloy, JA; Hajart, AF; Jethwa, PR; Liu, JK; Patel, TD | 1 |
| Ahuja, A; Bhardwaj, M; Dutta, D; Kulshreshtha, B; Sharma, L | 1 |
| Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S | 1 |
| D'Sylva, C; Fraser, LA; Khan, T; Van Uum, S | 1 |
| Ishikura, R; Koyama, H; Kurajoh, M; Moriwaki, Y; Namba, M; Okazaki, H; Shiraishi, J; Shirakawa, M; Shoji, T; Yamamoto, T | 1 |
| Bonaventura, MM; Calandra, RS; Huhtaniemi, IT; Lux-Lantos, VA; Poutanen, M; Ratner, LD; Rulli, SB; Stevens, G | 1 |
| Bellaviti Buttoni, P; Carosi, G; Ferrante, E; Filopanti, M; Malchiodi, E; Mantovani, G; Profka, E; Rodari, G; Sala, E; Spada, A; Verrua, E | 1 |
| Librizzi, R; Obermayer-Pietsch, B; Pieber, TR; Pilz, S; Schwetz, V; Stiegler, C; Theiler, G; Trummer, C | 1 |
| Anyiam, S; Baldeweg, FC; Baldeweg, SE; Bevan, JS; Butt, N; Drake, WM; Han, TS; Karavitaki, N; Kyriakakis, N; Martin, NM; Murray, RD; Parasuraman, SK; Rees, DA; Richardson, TI; Sheikh, UE; Steeds, RP; Stiles, CE; Stojanovic, N; Taylor, L; Toogood, AA; Trainer, PJ; Vaidya, B | 1 |
| Brue, T; Castinetti, F; Cebula, H; Goichot, B; Graillon, T; Képénékian, L | 1 |
| Auriemma, R; Beckers, A; Daly, AF; Dulgheru, R; Garcia, MT; Lancellotti, P; Magne, J; Maiga, I; Petrossians, P; Rubio-Almanza, M; Vroonen, L | 1 |
| Nachtigall, LB | 1 |
| Atkin, SL; Clark, AL; Kallvikbacka-Bennett, A; Rigby, AS; Wakil, A | 1 |
| Belleville, I; Boujon, B; Chagué, F; Petit, JM | 2 |
| Banerjee, A; Hatfield, EC; Martin, NM; Meeran, K; Tan, T; Williamson, C; Wynne, K | 1 |
| Jin, ZM | 1 |
| Blevins, LS; Byrd, BF; Devin, JK; Lakhani, VT | 1 |
| Burri, E; Nüesch, R; Zulewski, H | 1 |
| Sherlock, M; Steeds, R; Toogood, AA | 1 |
| Bogazzi, F; Lombardi, M; Manetti, L; Martino, E; Raffaelli, V; Rossi, G | 1 |
| Martin, NM; Meeran, K; Tan, T | 1 |
| Kharlip, J; Salvatori, R; Wand, GS; Yenokyan, G | 1 |
| Pullan, PT | 1 |
| Biller, BM; Grinspoon, S; Klibanski, A; Lawson, EA; Lo, J; McCarty, D; Miller, KK; Nachtigall, LB; Passeri, J; Utz, A; Valassi, E | 1 |
| Cervantes, CE; Da Costa, CV; Hernando, CA; Vargas, ML | 1 |
| Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM | 1 |
| Molitch, ME | 2 |
| Amano, K; Hori, T; Izumi, S; Kawamata, T; Makino, R; Miki, N; Okada, Y; Ono, M; Seki, T; Takano, K | 1 |
| Bernard, P; Hubinont, C; Lebbe, M; Maiter, D | 1 |
| Bahceci, M; Sismanoglu, A; Ulug, U | 1 |
| Babakhani, L; Fereshtehnejad, SM; Mojthahedi, K; Motazedian, S | 1 |
| Baynes, KC; Cabrita, IZ; Dhillo, WS; Eliahoo, J; Grogono, J; Hensman, D; Martin, NM; Meeran, K; Nihoyannopoulos, P; Robinson, S; Tan, T | 1 |
| Balcik, O; Buyukbayrak, EE; Karageyim Karsidag, AY; Kars, B; Pirimoglu, M; Turan, C; Unal, O | 1 |
| Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein-Day, P; García-Basavilbaso, N; Glerean, M; Gollan, V; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, NM | 1 |
| Bianchi, A; Carrozza, C; D'Ercole, M; Della Pepa, GM; Doglietto, F | 1 |
| Boguszewski, CL; dos Santos Nunes, V; El Dib, R; Nogueira, CR | 1 |
| Chanson, P; Maison, P; Sandret, L | 1 |
| Harrisson, SE; Mathad, NV; Zaben, MJ | 1 |
| Gibson, CD; Karmally, W; Korner, J; McMahon, DJ; Wardlaw, SL | 1 |
| Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
| Bussone, G; Moschiano, F; Usai, S | 1 |
| Anholm, C; Baltzar, MT; Petersen, CD | 1 |
| Giampietro, A; Iacovazzo, D; Lugli, F | 1 |
| Cobo, J; Coronas, R; Giménez-Palop, O; Márquez, M; Ortega, E | 1 |
| Beck-Peccoz, P; Beckers, A; Borson-Chazot, F; Brue, T; Caron, P; Chanson, P; Ciccarelli, E; Daly, AF; Delemer, B; Gatta, B; Jaffrain-Rea, ML; Naves, LA; Petrossians, P; Tamagno, G; Vilar, L; Vroonen, L | 1 |
| Shahzad, H; Sheikh, A; Sheikh, L | 1 |
| Ahtiainen, P; Calandra, RS; Di Giorgio, NP; Gonzalez, B; Huhtaniemi, IT; Poutanen, M; Ratner, LD; Rulli, SB | 1 |
| Auriemma, RS; Colao, A; Di Sarno, A; Gasperi, M; Grasso, LF; Guerra, E; Perone, Y; Pivonello, R | 1 |
| Anand, KS; Dhikav, V | 1 |
| Abaci, A; Altincik, A; Bober, E; Buyukgebiz, A; Can, S; Catli, G; Demir, K | 1 |
| Bretz, F; Hothorn, LA | 1 |
| Mah, PM; Webster, J | 1 |
| Freda, PU; Korner, J; Lo, J; Wardlaw, SL | 1 |
| Cavallero, D; Fazzuoli, L; Giusti, M; Valenti, S | 1 |
| Biondi, B; Briganti, F; Cappabianca, P; Colao, A; Faggiano, A; Lombardi, G; Pivonello, R; Sarno, AD; Somma, CD | 1 |
| Buchfelder, M; Harms, E; Hüfner, M; Saeger, W; Siggelkow, H | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Cappabianca, P; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Pivonello, R | 1 |
| Colao, A; De Rosa, M; Di Somma, C; Lombardi, G; Orio, F; Tauchmanova', L; Vitale, G; Zarrilli, S | 1 |
| Friedman, TC | 1 |
| Couldwell, WT; Laws, ER; Weiss, MH | 1 |
| Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E | 1 |
| Hermus, AR; Nooijen, P; Pieters, GF; van Alfen, N; van Lindert, E; van Uum, SH; Wesseling, P | 1 |
| Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
| Abs, R; Verhelst, J | 1 |
| Delgrange, E; Gustin, T | 1 |
| Crosignani, PG | 1 |
| Boianov, M; Khristov, V; Vezenkova, L | 1 |
| Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML | 1 |
| Delgrange, E | 1 |
| Barlier, A; Jaquet, P | 1 |
| Ciccarelli, A; Colao, A; De Rosa, M; Di Sarno, A; Gaccione, M; Guerra, E; Lombardi, G; Zarrilli, S | 1 |
| Beauchamp, MC; Li, L; Maingrette, F; Mamputu, JC; Renier, G; Serri, O | 1 |
| Fleseriu, M; Hamrahian, AH; Lee, M; Pineyro, MM; Reddy, SK; Siraj, ES; Skugor, M | 1 |
| Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A | 1 |
| Brändle, M; Schmid, C | 1 |
| Khandwala, HM | 1 |
| Atkinson, AB; Cooke, RS; Herron, B; Hunter, SJ; McCall, D; Sheridan, B | 1 |
| Christ, ER; Jenni, S; Seiler, R; Stettler, C | 1 |
| Mascarell, S; Sarne, DH | 1 |
| Bowsher, T; Chatfield, J; Loskutoff, N; O'Neill, K; Ramey, J; Zhang, L | 1 |
| Tokhunts, KA | 1 |
| Ionescu, A; Price, DE; Stephens, JW | 1 |
| Chuang, E; Molitch, ME | 1 |
| Briganti, F; Cappabianca, P; Caranci, F; Cavallo, LM; Cirillo, S; Colao, A; Di Sarno, A; Elefante, A; Guerra, E; Lombardi, G; Pivonello, R | 1 |
| Abs, R; Bárcena, DG; Chanson, P; Colao, A; Kleinberg, DL; Paulus, W | 1 |
| Bellastella, A; Bellastella, G; Bizzarro, A; Colao, A; Conte, M; Coronella, C; De Bellis, A; Lombardi, G; Pasquali, D; Pivonello, R; Savoia, A; Sinisi, AA | 1 |
| Caldas, D; Cesar de Oliveira Naliato, E; Colao, A; Dutra Violante, AH; Fontes, R; Gomes de Souza, R; Guerra, E; Lamounier Filho, A; Rezende Loureiro, C; Schrank, Y; Sebastian, A; Vaisman, M | 1 |
| Katzman, P; Lindgren, H; Löndahl, M; Nilsson, A | 1 |
| Duarte, J; Fernández-Reyes, MJ; Heras, M; Iglesias, P; Jiménez, MJ; Muñoz, H; Sánchez, R; Tajada, P | 1 |
| Bogazzi, F; Boresi, F; Buralli, S; Cigni, T; Lombardi, M; Manetti, L; Martino, E; Raffaelli, V; Salvetti, A; Taddei, S | 1 |
| Bryson, HM; Fitton, A; Rains, CP | 1 |
| Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G | 1 |
| Bevan, JS; Davis, JR | 1 |
| Ciccarelli, E; D'Alberton, A; Falsetti, L; Ferrari, C; Fioretti, P; Giordano, G; L'Hermite, M; Piscitelli, G; Polli, A; Webster, J | 2 |
| Fraser, RB; Jones, TH | 1 |
| Carraro, A; Cuttica, M; Giordano, G; Giusti, M; Porcella, E; Valenti, S | 1 |
| Ferrari, CI; Ismail, I; Piscitelli, G; Polli, A; Scanlon, MF; Webster, J | 1 |
| Serri, O | 1 |
| Colombo, N; D'Alberton, A; de Vincentiis, S; Marchini, M; Motta, T | 1 |
| Crosignani, PG; Ferrari, C; Piscitelli, G | 1 |
| Webster, J | 2 |
| Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C | 1 |
| Bertagna, A; Camanni, F; Camanni, M; Cammarota, T; Ciccarelli, E; Cirillo, S; Gaia, D; Grottoli, S; Razzore, P | 1 |
| Colao, A; Di Sarno, A; Di Somma, C; Facciolli, G; Klain, M; Landi, ML; Lombardi, G; Panza, N; Pivonello, R; Salvatore, M | 1 |
| Conner, P; Fried, G | 1 |
| Colao, A; De Rosa, M; Di Sarno, A; Ferone, D; Landi, ML; Lombardi, G; Merola, B; Paesano, L; Zarrilli, S | 1 |
| Chervin, A; Fideleff, HL; Gurucharri, C; Holland, ME; Sinai, I | 1 |
| Coppola, A; Cuomo, MA | 1 |
| Colao, A; Lombardi, G | 1 |
| Inada, Y; Kojima, M; Komatsu, H; Miyata, H; Moro, M; Torii, R | 1 |
| Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J | 1 |
| Ballaux, D; De Deyn, PP; Mahler, C; Pickut, B; Verhelst, J | 1 |
| Dimitriadis, A; Galli-Tsinopoulou, A; Karamouzis, M; Mitsiakos, G; Nousia-Arvanitakis, S | 1 |
| Tomov, I | 1 |
| Tollin, SR | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Papaleo, E | 1 |
| Annunziato, L; Colao, A; Lombardi, G | 1 |
| Miki, N | 1 |
| Arikan, E; Hatemi, H; Sabuncu, T; Tasan, E | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Marelli, G; Marsiglio, E; Papaleo, E; Rofena, S | 1 |
| Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW | 1 |
| Biederman, J; Cohen, LG | 1 |
| Crosignani, P; D'Alberton, A; de Vincentiis, S; Ferrari, C; Mattei, AM; Paracchi, A | 1 |
| Ambrosi, B; Conti, A; Faglia, G; Morabito, F; Muratori, M; Sartorio, A | 1 |
| Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F | 1 |
| Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D | 1 |
| Durante, R; Giordano, G; Giusti, M; Lomeo, A; Mazzocchi, G; Sghedoni, D; Torre, R | 1 |
| Crosignani, PG; Faglia, G; Ferrari, C; Mattei, A; Melis, GB; Muratori, M; Paracchi, A; Sghedoni, D | 1 |
| Baroldi, P; Cavioni, V; Crosignani, PG; Ferrari, C; Galparoli, C; Gerevini, G; Mattei, AM; Paracchi, A; Romano, C; Spellecchia, D | 1 |
| Baroldi, P; Beneventi, F; Fioretti, P; Gambacciani, M; Mais, V; Melis, GB; Paoletti, AM | 1 |
| Barbieri, C; Boghen, M; Caldara, R; Codecasa, F; Dubini, A; Ferrari, C; Mucci, M; Paracchi, A; Romano, C | 1 |
34 review(s) available for cabergoline and Hyperprolactinemia
| Article | Year |
|---|---|
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Topics: Bromocriptine; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Parkinson Disease; Restless Legs Syndrome | 2022 |
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Topics: Bromocriptine; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 2022 |
Metabolic effects of prolactin.
Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain | 2022 |
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms | 2023 |
How to manage intolerance to dopamine agonist in patients with prolactinoma.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2023 |
Late-onset symptomatic hyperprolactinemia in 6-pyruvoyl-tetrahydropterin synthase deficiency.
Topics: Adolescent; Adult; Cabergoline; Female; Humans; Hyperprolactinemia; Infant, Newborn; Levodopa; Male; Phenylketonurias; Prolactin | 2023 |
Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review.
Topics: Administration, Oral; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Middle Aged; Postpartum Period; Young Adult | 2020 |
[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Parkinson Disease; Ultrasonography | 2014 |
Prolactinomas, cabergoline, and pregnancy.
Topics: Animals; Antineoplastic Agents; Cabergoline; Ergolines; Female; Fetal Development; Humans; Hyperprolactinemia; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2014 |
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Topics: Biomarkers, Tumor; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Update on prolactinomas. Part 2: Treatment and management strategies.
Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus | 2015 |
Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Odds Ratio; Osteoporotic Fractures; Pituitary Neoplasms; Prevalence; Prolactinoma; Sex Factors; Spinal Fractures | 2015 |
Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
Topics: Aortic Valve; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Mental Disorders; Mitral Valve; Risk Factors; Tricuspid Valve | 2008 |
[Cabergoline in hyperprolactinemia and valvular heart disease].
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Ultrasonography | 2009 |
Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gestational Age; Humans; Hyperprolactinemia; Middle Aged; Pregnancy; Pregnancy Complications; Premature Birth; Prolactin; Retrospective Studies; Young Adult | 2010 |
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Randomized Controlled Trials as Topic | 2011 |
Place of cabergoline in acromegaly: a meta-analysis.
Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Data Interpretation, Statistical; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Male; Middle Aged; Somatostatin; Treatment Outcome | 2011 |
Prolactinoma in pregnancy.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fetus; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2011 |
How to investigate and treat: headache and hyperprolactinemia.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Tension-Type Headache; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Hyperprolactinemia: etiology, diagnosis, and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Neurosurgical Procedures; Prevalence | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Hyperprolactinemia: pathophysiology and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative | 2003 |
Current treatment issues in female hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2006 |
Quinagolide--a valuable treatment option for hyperprolactinaemia.
Topics: Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Patient Compliance | 2006 |
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics | 2006 |
New drugs for hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Hormone Antagonists; Humans; Hyperprolactinemia | 1995 |
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Prolactin; Tissue Distribution | 1995 |
Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Postpartum Period; Randomized Controlled Trials as Topic | 1995 |
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Male; Pregnancy | 1996 |
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin | 1998 |
[Prolactinoma in the male. Physiopathological, clinical, and therapeutic features].
Topics: Cabergoline; Cranial Irradiation; Dopamine Agonists; Erectile Dysfunction; Ergolines; Galactorrhea; Gynecomastia; Humans; Hyperprolactinemia; Hypophysectomy; Infertility, Male; Libido; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 1998 |
Growth-hormone and prolactin excess.
Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Somatostatin | 1998 |
Ectopic macroprolactinoma mimicking a chordoma: a case report.
Topics: Aged; Aged, 80 and over; Amnesia, Retrograde; Antineoplastic Agents; Cabergoline; Chordoma; Cranial Fossa, Posterior; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Headache; Humans; Hyperprolactinemia; Luteinizing Hormone; Magnetic Resonance Imaging; Prolactinoma; Skull Base Neoplasms | 1999 |
Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
Topics: Age Factors; Antipsychotic Agents; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Retrospective Studies; Risperidone | 2001 |
26 trial(s) available for cabergoline and Hyperprolactinemia
| Article | Year |
|---|---|
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
Color Doppler analysis of uterine, spiral, and intraovarian artery blood flow before and after treatment with cabergoline in hyperprolactinemic patients.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Ovary; Pilot Projects; Regional Blood Flow; Ultrasonography; Uterine Artery; Uterus; Young Adult | 2015 |
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Insemination, Artificial | 2010 |
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Topics: Adolescent; Adult; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult | 2010 |
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Topics: Adolescent; Adult; Blood Glucose; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Glucose Tolerance Test; Humans; Hyperprolactinemia; Male; Middle Aged; Obesity; Pilot Projects; Prolactin; Weight Loss; Young Adult | 2012 |
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Luteal Phase; Menstrual Cycle; Nitric Oxide; Ovulation; Pituitary Neoplasms; Progesterone; Prolactinoma; Reference Values | 2002 |
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Follow-Up Studies; Galactose; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Sex Characteristics; Sexual Dysfunction, Physiological; Treatment Outcome; Visual Fields; Weight Gain | 2003 |
Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.
Topics: Adult; Cabergoline; Case-Control Studies; Circadian Rhythm; Dopamine Agonists; Drug Administration Schedule; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Middle Aged; Penile Erection; Testosterone; Treatment Outcome | 2004 |
[Suppression of hyperprolactinemia in pituitary microadenoma with cabergoline (Dostinex)].
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Tumor Burden | 2005 |
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; E-Selectin; Enzyme-Linked Immunosorbent Assay; Ergolines; Female; Humans; Hyperprolactinemia; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Linear Models; Lipids; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha | 2006 |
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome | 2007 |
Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
Topics: Abortion, Spontaneous; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy; Pregnancy Outcome; Prospective Studies | 2008 |
Quality of life in women with microprolactinoma treated with dopamine agonists.
Topics: Adult; Antineoplastic Agents; Brazil; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Health Status Indicators; Humans; Hyperprolactinemia; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome | 2008 |
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; France; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Prospective Studies | 1995 |
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
Topics: Adult; Cabergoline; Dopamine Agents; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy; Prospective Studies; Time Factors | 1993 |
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Topics: Administration, Oral; Adult; Aminoquinolines; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin | 1994 |
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin | 1994 |
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin | 1997 |
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Topics: Adult; Aminoquinolines; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies | 1998 |
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Follow-Up Studies; Hormones; Humans; Hyperprolactinemia; Libido; Male; Penile Erection; Prolactin; Semen; Time Factors | 1998 |
[Treatment of hyperprolactinemic amenorrhea with cabergoline].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Prolactin; Treatment Outcome | 1997 |
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 2001 |
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies | 2001 |
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Topics: Adolescent; Adult; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prospective Studies | 1992 |
Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Topics: Administration, Oral; Adolescent; Adult; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Placebos; Prolactin; Prolactinoma; Radiography | 1989 |
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Prolactin | 1988 |
134 other study(ies) available for cabergoline and Hyperprolactinemia
| Article | Year |
|---|---|
[Hyperprolactinemia in the postmenopause: versions and contraversions].
Topics: Cabergoline; Dopamine Agonists; Estrogens; Female; Humans; Hyperprolactinemia; Neoplasm Recurrence, Local; Pituitary Neoplasms; Postmenopause; Progestins; Prolactin; Prolactinoma | 2021 |
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Topics: Adolescent; Cabergoline; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Infant; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2022 |
Galactorrhea: Rapid Evidence Review.
Topics: Cabergoline; Female; Galactorrhea; Humans; Hyperprolactinemia; Pituitary Neoplasms; Pregnancy; Prolactin; Thyrotropin | 2022 |
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Cholesterol; Creatinine; Female; Fibrinogen; Glycated Hemoglobin; Hashimoto Disease; Humans; Hyperprolactinemia; Insulin Resistance; Lipoproteins, HDL; Prolactin; Risk Factors; Thyroiditis, Autoimmune; Uric Acid | 2023 |
Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Glucose; Humans; Hyperprolactinemia; Pilot Projects; Prolactin; Risk Factors; Triglycerides; Uric Acid; Vitamin D; Vitamin D Deficiency; Vitamins | 2023 |
The link between seizures and prolactin: A study on the effects of anticonvulsant medications on hyperprolactinemia in rats.
Topics: Animals; Anticonvulsants; Cabergoline; Female; Hyperprolactinemia; Levetiracetam; Prolactin; Rats; Rats, Wistar; Seizures | 2023 |
A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas.
Topics: Abortion, Spontaneous; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma; Retrospective Studies; Young Adult | 2020 |
Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
Topics: Adult; Cabergoline; California; Cross-Sectional Studies; Dopamine Agonists; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prognosis; Young Adult | 2020 |
Clinical profile and early therapeutic response to cabergoline of patients with hyperprolactinemia in a Cameroonian population.
Topics: Adult; Cabergoline; Cameroon; Cross-Sectional Studies; Dopamine Agonists; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Treatment Outcome; Young Adult | 2020 |
Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Biomarkers, Tumor; Cabergoline; Cohort Studies; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary Neoplasms; Prolactinoma; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Withholding Treatment; Young Adult | 2021 |
Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.
Topics: Adult; Biomarkers; Cabergoline; Case-Control Studies; Cohort Studies; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Incidence; London; Male; Middle Aged; Pituitary Neoplasms; Primary Health Care; Prolactinoma | 2021 |
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Topics: Behavioral Symptoms; Cabergoline; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Italy; Male; Middle Aged; Pituitary Diseases; Prevalence; Risk Factors; Surveys and Questionnaires | 2021 |
Letter to "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?"
Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2021 |
Response to Letter to the Editor: "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?"
Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2021 |
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Prolactin; Prolactinoma; Prospective Studies | 2022 |
True hyperprolactinemia in men without visible pituitary adenoma.
Topics: Adenoma; Adult; Aged; Cabergoline; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2021 |
Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Topics: Adiposity; Adult; Austria; Body Composition; Body Mass Index; Cabergoline; Case-Control Studies; Dyslipidemias; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Lipid Metabolism; Male; Middle Aged; Overweight; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2021 |
Treatment of hyperprolactinemia: A single-institute experience.
Topics: Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Male; Middle Aged | 2021 |
Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Outcome Assessment, Health Care; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
Topics: Adult; Cabergoline; Cognition; Dopamine Agonists; Drug Monitoring; Female; Humans; Hyperprolactinemia; Male; Mental Status and Dementia Tests; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 2018 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Topics: Adult; Antineoplastic Agents, Hormonal; Cabergoline; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hyperprolactinemia; Lectins, C-Type; Medroxyprogesterone Acetate; Retrospective Studies; Young Adult | 2018 |
Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
Topics: Acromegaly; Adult; Aged; Cabergoline; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Receptors, Somatostatin; Retrospective Studies; Young Adult | 2018 |
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Tumor Burden; Young Adult | 2018 |
Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Topics: Adult; Anthropometry; Body Weight; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Insulin Resistance; Metabolome; Middle Aged; Prolactinoma; Treatment Outcome; Waist Circumference; Young Adult | 2019 |
Response to Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline".
Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence | 2019 |
Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline".
Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence | 2019 |
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk; Treatment Outcome; Young Adult | 2019 |
Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Cohort Studies; Erectile Dysfunction; Humans; Hyperprolactinemia; Israel; Male; Osteoporosis; Prolactin; Prolactinoma; Retrospective Studies; Testosterone; Treatment Outcome | 2019 |
Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
Topics: Adult; Aged; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Impulsive Behavior; Male; Middle Aged; Pilot Projects; Prevalence; Psychometrics; Self Report; Surveys and Questionnaires; Treatment Outcome | 2014 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunction, Physiological; Sulpiride | 2013 |
A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom | 2014 |
Prolactinoma-associated headache and dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Substance Withdrawal Syndrome | 2014 |
Effect of cabergoline on metabolism in prolactinomas.
Topics: Adiposity; Adult; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Male; Metabolic Diseases; Metabolic Syndrome; Pituitary Neoplasms; Prevalence; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
Women with prolactinomas presented at the postmenopausal period.
Topics: Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Middle Aged; Pituitary Neoplasms; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome | 2014 |
Lesson of the month (1): cabergoline - 'i eat funny on that'.
Topics: Adult; Bulimia; Cabergoline; Compulsive Behavior; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Impulsive Behavior; Self-Injurious Behavior | 2014 |
Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.
Topics: Adult; Cabergoline; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged | 2013 |
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma | 2014 |
AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Risk | 2014 |
Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
Topics: Animals; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Elephants; Ergolines; Estrous Cycle; Female; Hyperprolactinemia; Progestins; Prolactin | 2014 |
Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Treating prolactinoma can prevent autoimmune diseases.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Humans; Hyperprolactinemia; Multiple Sclerosis; Prolactin; Prolactinoma | 2015 |
Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Male; Metabolome; Middle Aged; Pituitary Neoplasms; Prolactinoma; Testosterone | 2015 |
SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cabergoline; Cohort Studies; Down-Regulation; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Remission Induction; Time Factors; Tumor Burden; Young Adult | 2015 |
Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Ergolines; Female; Health Care Costs; Hormone Antagonists; Humans; Hyperprolactinemia; Life Expectancy; Male; Medicare; Microsurgery; Middle Aged; Monte Carlo Method; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma; Quality-Adjusted Life Years; Sphenoid Sinus; Time Factors; Treatment Outcome; United States | 2016 |
Macular amyloidosis complicating macroprolactinoma--a novel clinical association.
Topics: Adrenal Insufficiency; Adult; Amyloidosis, Familial; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Macula Lutea; Male; Pituitary Neoplasms; Prolactinoma; Retinal Diseases; Skin Diseases, Genetic | 2015 |
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult | 2016 |
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Hyperprolactinemia; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactin; Prolactinoma | 2016 |
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice.
Topics: Animals; Blood Glucose; Cabergoline; Chorionic Gonadotropin, beta Subunit, Human; Ergolines; Female; Glucose Intolerance; Hyperinsulinism; Hyperprolactinemia; Hypertriglyceridemia; Insulin; Insulin Resistance; Mice; Mice, Transgenic; Prolactin; Triglycerides | 2016 |
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Topics: Adult; Aged; Biomarkers; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosis; Prolactinoma; Tomography, X-Ray Computed; Withholding Treatment | 2016 |
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Topics: Adult; Cabergoline; Cholesterol; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2017 |
A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom | 2016 |
Long-term outcome of macroprolactinomas.
Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; France; Humans; Hyperprolactinemia; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Cabergoline for hyperprolactinemia: getting to the heart of it.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart; Humans; Hyperprolactinemia | 2017 |
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Topics: Adult; Cabergoline; Cross-Sectional Studies; Databases, Factual; Dopamine Agonists; Echocardiography; Echocardiography, Doppler, Color; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Risk Factors | 2008 |
[An aortic insufficiency diagnosed under cabergoline].
Topics: Aortic Valve Insufficiency; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged | 2009 |
High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
Topics: Adult; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma | 2009 |
[Some issues in the diagnosis and treatment of hyperprolactinemia].
Topics: Aminoquinolines; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Gland; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2008 |
Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
Topics: Adult; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged | 2008 |
[Hyperprolactinemia in a man's world].
Topics: Algorithms; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Follow-Up Studies; Gynecomastia; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Testosterone; Time Factors; Ultrasonography, Mammary | 2008 |
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
Topics: Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Parkinson Disease; Pergolide; Tricuspid Valve Insufficiency | 2009 |
Dopamine agonists and hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia | 2009 |
Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Prolactinoma; Recurrence; Retrospective Studies; Time Factors; Withholding Treatment; Young Adult | 2009 |
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography | 2009 |
Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Case-Control Studies; Echocardiography; Ergolines; Female; Heart Valves; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Sex Characteristics; Young Adult | 2010 |
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric | 2010 |
Pituitary gland: can prolactinomas be cured medically?
Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Meta-Analysis as Topic; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Recurrence; Withholding Treatment | 2010 |
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Topics: Adult; Birth Weight; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Progesterone; Prolactin; Prolactinoma | 2010 |
Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Prolactinoma; Retrospective Studies | 2010 |
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.
Topics: Adult; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Rate; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2010 |
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Topics: Adult; Antiparkinson Agents; Blood Pressure; Cabergoline; Cross-Sectional Studies; Dose-Response Relationship, Drug; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies; Risk Assessment; Ventricular Function, Left; Ventricular Function, Right | 2010 |
Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Female; Galactorrhea; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Menstruation Disturbances; Pituitary Neoplasms; Prolactin | 2010 |
Giant prolactinoma causing cranio-cervical junction instability: a case report.
Topics: Adult; Antineoplastic Agents; Arthrodesis; Cabergoline; Cervical Vertebrae; Cranial Fossa, Posterior; Cranial Nerve Diseases; Craniotomy; Ergolines; Humans; Hyperprolactinemia; Joint Instability; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Occipital Bone; Orthotic Devices; Pituitary Neoplasms; Prolactinoma; Recovery of Function; Treatment Outcome | 2011 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
[Hyperprolactin as cause of hypoactive sexual desire in men].
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological | 2012 |
Ectopic posterior pituitary causing hyperprolactinemia.
Topics: Adult; Cabergoline; Choristoma; Diagnosis, Differential; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Oligomenorrhea; Pituitary Diseases; Pituitary Gland, Posterior; Prolactin; Recurrence; Treatment Outcome | 2012 |
Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Treatment Outcome | 2012 |
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Chemotherapy, Adjuvant; Child; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins; Retrospective Studies; Treatment Failure | 2012 |
Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma | 2012 |
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
Topics: Animals; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Ergolines; Female; Fertility; Gene Expression Regulation; Humans; Hyperprolactinemia; Infertility; Mice; Mice, Transgenic; Ovulation; Phenotype; Time Factors | 2012 |
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Topics: Adult; Antineoplastic Agents; Breast Feeding; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Lactation; Observation; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Puerperal Disorders; Recurrence; Time Factors | 2013 |
Hyperprolactinemia: an unusual cause of erectile dysfunction.
Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Treatment Outcome | 2013 |
Hyperprolactinemia in children: clinical features and long-term results.
Topics: Adolescent; Bromocriptine; Cabergoline; Child; Combined Modality Therapy; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome | 2012 |
Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.
Topics: Cabergoline; Computer Simulation; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Hyperprolactinemia; Monte Carlo Method; Randomized Controlled Trials as Topic; Research Design; Sample Size | 2002 |
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
Topics: Anti-Obesity Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Weight Loss | 2003 |
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Topics: Cabergoline; Diagnosis, Differential; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Pituitary Gland; Pituitary Neoplasms; Postoperative Complications; Prolactinoma | 2003 |
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Recurrence; Withholding Treatment | 2003 |
Prolactinomas.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Withholding Treatment | 2004 |
Prolactinomas.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Withholding Treatment | 2004 |
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology | 2004 |
Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
Topics: Adult; Antineoplastic Agents; Brain Stem Neoplasms; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2004 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |
Cystic macroprolactinoma: primary medical treatment?
Topics: Adolescent; Cabergoline; Central Nervous System Cysts; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Treatment Outcome | 2005 |
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome | 2005 |
Cabergoline and mitral regurgitation.
Topics: Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Mitral Valve Insufficiency; Parkinson Disease | 2006 |
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Drug Administration Schedule; Ergolines; Gonadotropins; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Semen; Sperm Count; Spermatozoa; Testosterone; Time Factors; Treatment Outcome | 2006 |
Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
Topics: Abducens Nerve Diseases; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Oculomotor Nerve Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms; Trochlear Nerve Diseases | 2006 |
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Insulin Resistance; Obesity; Risk Factors | 2006 |
Macroprolactinemia in a patient with infertility and hyperprolactinemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Prolactin | 2006 |
Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactinoma | 2007 |
[Simultaneous defect of visual fields and loss of libido--a coincidence?].
Topics: Cabergoline; Diagnosis, Differential; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Compression Syndromes; Optic Nerve Diseases; Pituitary Neoplasms; Prolactinoma; Visual Fields | 2006 |
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone | 2007 |
Resolution of a hyperprolactinemia in a western lowland gorilla (Gorilla gorilla gorilla).
Topics: Animals; Antineoplastic Agents; Ape Diseases; Cabergoline; Ergolines; Female; Gorilla gorilla; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Reproduction; Treatment Outcome | 2006 |
Dopamine agonists and valvular heart disease.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Ventricular Remodeling | 2007 |
Prolactin and autoimmune diseases in humans.
Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cyclosporine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Hyperprolactinemia; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Mice; Mice, Knockout; Penicillamine; Prednisone; Prolactin; Rats; Receptors, Prolactin | 2007 |
Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kaplan-Meier Estimate; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Prospective Studies; Regression Analysis; Remission Induction; ROC Curve; Secondary Prevention; Sex Distribution; Time Factors; Young Adult | 2007 |
[Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia].
Topics: Aortic Valve Insufficiency; Cabergoline; Diagnosis, Differential; Dopamine Agents; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Middle Aged; Receptor, Serotonin, 5-HT2B | 2007 |
Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Pituitary Diseases; Pituitary Function Tests; Pituitary Gland; Seroepidemiologic Studies; Thyroid Hormones; Thyrotropin; Time Factors | 2008 |
A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Pericardiectomy; Pericarditis, Constrictive | 2008 |
Nephrotic-range proteinuria in a patient with a giant prolactinoma.
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Proteinuria | 2008 |
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Topics: Adult; Aortic Valve Insufficiency; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Mitral Valve Insufficiency; Risk Factors; Tricuspid Valve Insufficiency | 2008 |
Cabergoline: an advance in dopaminergic therapy.
Topics: Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Patient Compliance; Pregnancy; Prolactin | 1994 |
Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy | 1994 |
Progress in the management of hyperprolactinemia.
Topics: Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia | 1994 |
Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Vagina | 1996 |
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin | 1997 |
New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Topics: Animals; Anovulation; Bromocriptine; Cabergoline; Callithrix; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Ergolines; Estradiol; Female; Hyperprolactinemia; Menstrual Cycle; Progesterone; Prolactin; Sulpiride; Time Factors | 1999 |
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics | 1999 |
Dopamine agonist therapy in hyperprolactinemia.
Topics: Aminoquinolines; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pregnancy; Pregnancy Complications | 1999 |
Osteopenia in children and adolescents with hyperprolactinemia.
Topics: Adolescent; Antineoplastic Agents; Bone Density; Bone Diseases, Metabolic; Cabergoline; Child; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed | 2000 |
[Dostinex (cabergoline)- a significant advance in prolactin control].
Topics: Administration, Oral; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Luteinizing Hormone; Receptors, Dopamine D2; Time Factors; Treatment Outcome | 2000 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Psychotic Disorders; Risperidone | 2000 |
Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.
Topics: Adult; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Embryo Transfer; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Hyperprolactinemia; Luteolytic Agents; Oocytes; Prolactin; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome; Triptorelin Pamoate | 2000 |
Cabergoline.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pregnancy | 2000 |
Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2001 |
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Infertility, Female; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Recombinant Proteins; Time Factors; Ultrasonography | 2001 |
Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Menstruation Disturbances; Middle Aged; Ovulation; Pituitary Neoplasms; Prolactinoma | 1992 |
Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Density; Cabergoline; Dihydroergotoxine; Dopamine Agents; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Osteocalcin; Pituitary Neoplasms; Prolactin; Prolactinoma | 1990 |
New perspectives in medical management of hyperprolactinemia.
Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 1990 |
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin | 1989 |
Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
Topics: Adult; Cabergoline; Dopamine Agents; Ergolines; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Stimulation, Chemical; Thyrotropin; Thyrotropin-Releasing Hormone; Time Factors | 1989 |
Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cabergoline; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Menstrual Cycle; Middle Aged; Postpartum Period; Pregnancy; Prolactin; Receptors, Dopamine | 1987 |
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Topics: Adult; Aged; Blood Pressure; Bromocriptine; Cabergoline; Ergolines; Female; Growth Hormone; Humans; Hyperprolactinemia; Male; Middle Aged; Time Factors | 1986 |